2023 North America Conference on Lung Cancer (NACLC) - Posters and Abstracts-PP01.112 Davey Daniel NACLC23 Abstract

PP01.112 Davey Daniel NACLC23 Abstract

Pdf Summary

This study aimed to evaluate the treatment patterns and outcomes for patients with advanced non-small cell lung cancer (aNSCLC) who received second-line (2L) treatment after prior platinum chemotherapy and immunotherapy combination therapy. The researchers utilized a nationwide electronic health record database to identify patients who initiated 2L treatment with non-platinum-based chemotherapy between January 2019 and June 2021.<br /><br />The study included 539 eligible patients with a median age of 68 years and the majority had non-squamous histology. The most commonly received 2L treatments were docetaxel plus ramucirumab combination therapy (45.1%), followed by docetaxel monotherapy (18.9%) and gemcitabine monotherapy (14.1%).<br /><br />The median overall survival (OS) was similar across the different treatments, ranging from 5.4 to 6.5 months. The median time to treatment discontinuation (TTD) and time to next treatment (TTNT) outcomes were also comparable across the treatments.<br /><br />The study found that patients who had fewer administrations of prior immunotherapy treatment and higher Eastern Cooperative Oncology Group (ECOG) scores had significantly shorter survival on 2L treatment.<br /><br />The study highlights the limited treatment options and poor prognosis for patients with aNSCLC in the real-world setting who receive 2L treatment after prior 1L platinum chemotherapy and immunotherapy combination therapy. It emphasizes the need for new treatment options in this setting. However, the subgroup of patients potentially eligible for clinical trials had better survival outcomes compared to the overall real-world cohort.<br /><br />In conclusion, this study provides real-world evidence on the treatment patterns and outcomes for patients with aNSCLC who receive 2L treatment after prior platinum chemotherapy and immunotherapy combination therapy. It underscores the importance of developing new treatment options to improve the prognosis for these patients.

Keywords

advanced non-small cell lung cancer

second-line treatment

platinum chemotherapy

immunotherapy combination therapy

electronic health record database

overall survival

time to treatment discontinuation

Eastern Cooperative Oncology Group

real-world setting

prognosis